Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
St. Jude Children's Research Hospital Children's Hospital of Philadelphia National Cancer Institute (NCI) |
---|---|
Information provided by: | St. Jude Children's Research Hospital |
ClinicalTrials.gov Identifier: | NCT00187057 |
This is a pilot/feasibility study designed to investigate the feasibility of treating children with Ataxia-Telangiectasia (A-T) and cancer with regimens nearly as intense as non-A-T patients with cancer would receive.
Condition | Intervention |
---|---|
Ataxia-Telangiectasia |
Drug: vinblastine, vincristine, prednisone, daunorubicin Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase Drug: etoposide, cytarabine, mercaptopurine Drug: dexamethasone, procarbazine Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia |
Estimated Enrollment: | 30 |
Study Start Date: | September 2002 |
Estimated Study Completion Date: | September 2012 |
Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1
Acute Lymphoblastic Leukemia (ALL) Low Risk
|
Drug: vinblastine, vincristine, prednisone, daunorubicin
See Detailed Description section for details of treatment interventions.
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
See Detailed Description section for details of treatment interventions.
Drug: etoposide, cytarabine, mercaptopurine
See Detailed Description section for details of treatment interventions.
Drug: dexamethasone, procarbazine
See Detailed Description section for details of treatment interventions.
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
See Detailed Description section for details of treatment interventions.
|
2
Acute Lymphoblastic Leukemia (ALL) - High Risk
|
Drug: vinblastine, vincristine, prednisone, daunorubicin
See Detailed Description section for details of treatment interventions.
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
See Detailed Description section for details of treatment interventions.
Drug: etoposide, cytarabine, mercaptopurine
See Detailed Description section for details of treatment interventions.
Drug: dexamethasone, procarbazine
See Detailed Description section for details of treatment interventions.
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
See Detailed Description section for details of treatment interventions.
|
3A
B-Cell Non-Hodgkins Lymphoma (Group A)
|
Drug: vinblastine, vincristine, prednisone, daunorubicin
See Detailed Description section for details of treatment interventions.
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
See Detailed Description section for details of treatment interventions.
Drug: etoposide, cytarabine, mercaptopurine
See Detailed Description section for details of treatment interventions.
Drug: dexamethasone, procarbazine
See Detailed Description section for details of treatment interventions.
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
See Detailed Description section for details of treatment interventions.
|
3B
B-Cell Non-Hodgkins Lymphoma (Group B)
|
Drug: vinblastine, vincristine, prednisone, daunorubicin
See Detailed Description section for details of treatment interventions.
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
See Detailed Description section for details of treatment interventions.
Drug: etoposide, cytarabine, mercaptopurine
See Detailed Description section for details of treatment interventions.
Drug: dexamethasone, procarbazine
See Detailed Description section for details of treatment interventions.
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
See Detailed Description section for details of treatment interventions.
|
4
Hodgkins Disease
|
Drug: vinblastine, vincristine, prednisone, daunorubicin
See Detailed Description section for details of treatment interventions.
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
See Detailed Description section for details of treatment interventions.
Drug: etoposide, cytarabine, mercaptopurine
See Detailed Description section for details of treatment interventions.
Drug: dexamethasone, procarbazine
See Detailed Description section for details of treatment interventions.
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
See Detailed Description section for details of treatment interventions.
|
Ages Eligible for Study: | up to 10 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Tennessee | |
St. Jude Children's Research Hospital | |
Memphis, Tennessee, United States, 38105 |
Principal Investigator: | John T. Sandlund, MD | St. Jude Children's Research Hospital |
Responsible Party: | St. Jude Children's Research Hospital ( John T. Sandlund, MD/Principle Investigator ) |
Study ID Numbers: | AT-1 |
Study First Received: | September 12, 2005 |
Last Updated: | February 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00187057 History of Changes |
Health Authority: | United States: Institutional Review Board |
Ataxia alphafetoprotein |
Dexamethasone Anti-Inflammatory Agents Prednisone Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Vinblastine 6-Mercaptopurine Brain Diseases Hormones Methotrexate Ataxia Telangiectasia Metabolic Disorder Etoposide Asparaginase |
Metabolic Diseases Antineoplastic Agents, Hormonal Vincristine Dyskinesias Glucocorticoids Doxorubicin Folic Acid Cerebellar Ataxia Procarbazine Antineoplastic Agents, Phytogenic Spinocerebellar Ataxias Antimetabolites Daunorubicin Ataxia-Telangiectasia Immunologic Factors |
Anti-Inflammatory Agents Dexamethasone Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action DNA Repair-Deficiency Disorders Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Vinblastine 6-Mercaptopurine Brain Diseases Hormones Therapeutic Uses Abortifacient Agents Methotrexate |
Cardiovascular Diseases Ataxia Telangiectasia Dermatologic Agents Nucleic Acid Synthesis Inhibitors Asparaginase Metabolic Diseases Antineoplastic Agents, Hormonal Immune System Diseases Nervous System Diseases Abortifacient Agents, Nonsteroidal Glucocorticoids Dyskinesias Doxorubicin Cerebellar Ataxia Procarbazine |